Resistance mutations against HCV protease inhibitors and antiviral drug design

Current Pharmaceutical Design

Volumn 20, Issue 5, 2014, Pages 694-703

  Shang, Luqing ^a   Lin, Kai ^b   Yin, Zheng ^a  

^a NANKAI UNIVERSITY   (China)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Hepatitis c virus; Protease inhibitor; Resistance

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; DANOPREVIR; FALDAPREVIR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; PEGINTERFERON ALPHA; PROTEINASE INHIBITOR; SIMEPREVIR; TELAPREVIR; VANIPREVIR;

ANTIVIRAL THERAPY; DRUG DESIGN; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; LIFE CYCLE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; VIROGENESIS; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; WILD TYPE;

ANIMALS; ANTIVIRAL AGENTS; CARRIER PROTEINS; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HUMANS; MOLECULAR CONFORMATION; MOLECULAR TARGETED THERAPY; MUTATION; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84895169891     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990008     Document Type: Review

References (83)

1. Nature Outlook: Hepatitis C. Nature 2011; 474: 1-21.
2. EASL Clinical Practice Guideline: Management of hepatitis C virus infection. J Hepatol 2011; 55: 245-64.
3. Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 Practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-44.
4. Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 2006; 25: 3834-47.
5. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002; 36: 47-56.
6. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29: 74-81.
7. Shepard CW, Finelli L, Alter MJ: Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-67.
8. Czepiel J, Biesiada G, Mach T: Viral hepatitis C. Pol Arch Med Wewn 2008; 118: 734-40.
9. Global Alert and Response (GAR), Hepatitis C. In World Health Organization; 2002.
10. Thein HH, Yi Q, Dore GJ, et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a metaanalysis and meta-regression. Hepatology 2008; 48: 418-31.
11. Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-21.
12. DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy A pathophysiologic Approach. 7th edition. McGraw-Hill Medical; 2008.
13. Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis 2011; 52: 889-900.
14. Rosen HR Chronic hepatitis C infection. N Engl J Med 2011; 364: 2429-39.
15. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006; 355: 2444-51.
16. Global Alert and Response (GAR), Hepatitis C. In World Health Organization; 2002.
17. Malcolm BA, Liu R, Agrawal S, et al. SCH 503034, a mechanismbased inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob. Agents Chemother 2006; 57: 1013-20.
18. Njoroge FG, Chen KX, Shih NY, Piwinski JJ. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Acc Chem Res 2008; 41: 50-9.
19. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
20. Poordad F, McCone J, Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
21. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-24.
22. Saadeh S, Davis GL. The evolving treatment of chronic hepatitis C: where we stand a decade out. Cleve Clin J Med 2004; 71(Suppl 3): 3-7.
23. Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. Lancet 2006; 368: 1106-18.
24. Sharma SD. Hepatitis C virus: molecular biology & current therapeutic options. Indian J Med Res 2010; 131: 17-34.
25. Kato N, Genome of human hepatitis C virus (HCV): gene organization, sequence diversity, and variation.Microb. Comp Genomics 2000; 5(3): 129-51.
26. Zeisel MB, Fofana I, Fafi-Kremer S, Baumert TF. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. J Hepatol 2011; 54: 566-76.
27. Dubuisson J. Hepatitis C virus proteins. World J. Gastroenterol 2007; 13(17): 2406-15.
28. Rong L, Perelson AS. Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling. Crit Rev Immunol 2010; 30: 131-48.
29. Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 2007; 132: 1979-98.
30. Nielsen SU, Bassendine MF, Burt AD, Bevitt DJ, Toms GL. Characterization of the genome and structural proteins of hepatitis C virus resolved from infected human liver. J Gen Virol 2004; 85: 1497-507.
31. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. Structural biology of hepatitis C virus. Hepatology 2004; 39: 5-19.
32. Bartenschlager R, Lohmann V. Replication of hepatitis C virus. J Gen Virol 2000; 81(Pt 7): 1631-48.
33. Love RA, Parge HE, Wickersham JA. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 1996; 87: 331-42.
34. Kim JL, Morgenstern KA, Lin C. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 1996; 87: 343-55.
35. Lin C, Lin K, Luong Y P, et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem 2004; 279: 17508-14.
36. Lin C, Gates C A, et al. In vitro studies of cross-resistance mutations against two Hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem 2005; 280: 36784-91.
37. Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 2006; 70: 28-38.
38. Susser S, Welsch C, Wang YL, Zettler M, Francisco SD, Ursula K. Characterization of resistance to the protease inhibitor Boceprevir in hepatitis C virus-infected patients. Hepatology 2009; 50: 1709-18.
39. Venkatraman S, Bogen SL, Arasappan A, Bennett F. 2 Discovery of (1R, 5S)-N-[3-Amino-1-(cyclobutylmethyl)-2-3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)-amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavail-able, hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection. J Med Chem 2006; 49: 6074-86.
40. Bartenschlager R. The NS3/4A proteinase of the hepatitis C virus: unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy. J Viral Hepatitis 1999; 10: 1-2.
41. Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003; 426: 186-9.
42. McHutchison J G, Manns M P, Muir A J, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362 (14): 1292-303.
43. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection.N Engl J Med 2011; 364 (25): 2417-28.
44. Bacon B, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364 (13): 1207-17.
45. Forestier N, Larrey D, Marcellin P, Guyader D. Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon-2a and ribavirin in patients with hepatitis C. J Infect Dis 2011; 204 (4): 601-8.
46. Larrey D, Carenco C, Guyader D. Sustained virological response after 14-day treatment with danoprevir and 48-week treatment with pegylated interferon-2a (40 KD) plus ribavirin. Antivir Ther 2012; 17: 927-32.
47. Manns MP, Gane E. Vaniprevir with peginterferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C-a randomized phase 2 study. Hepatology 2012; 56(3): 884-93.
48. Raboisson P, H de Kock, Å Rosenquist, Nilsson M. Structureactivity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of TMC435350. Bioorg Med Chem Lett 2008; 18: 4853-8.
49. Lin T I, Lenz O, Verbinnen T, Simmen K. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother 2009; 53: 1377-85.
50. Marcellin P, Reesink H, Berg T, Cramp M, Smedt G De Antiviral activity and safety of TMC435 combined with peginterferon alpha-2a and ribavirin in patients with genotype 1 hepatitis C infection who failed previous IFN-based therapy. J Hepatol 2009; 50: 385.
51. Montse LB, Murray DB, Nathali G. Discovery of a Potent and Selective Noncovalent Linear Inhibitor of the Hepatitis C Virus NS3 Protease (BI 201335). J Med Chem 2010; 53: 6466-76.
52. Michael P, Marc B, Yves B. Potency, safety, and pharmacokinetics of the NS3/4A protease ainhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol 2011; 54: 1114-22.
53. Summa V, Ludmerer S W, McCauley JA. MK-5172, a selective inhibitor of Hepatitis C Virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother 2012; 56(8): 4161-7.
54. Tong X, Bogen S, Chase R, et al. Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antiviral Res 2008; 77: 177-85.
55. Kieffer TL, Kwong AD, Picchio GR. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimicrob Chemother 2010; 65: 202-12.
56. Liverton NJ, Carroll SS, et al. MK-7009, a potent and selective inhibitor of Hepatitis C virus NS3/4A protease. Antimicrob Agents Chemother 2010; 54: 305-11.
57. Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol 2011; 55: 192-206.
58. Keith PR, Akbar A, William E. Royer, Celia AS. Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. PNAS 2010; 107: 20986-91.
59. Seiwert SD, Hon J, Lim SR, Wang T, Tan H, Blatt LM. Sequence variation of NS3/4A in HCV replicons exposed to ITMN-191 concentrations encompassing those likely to be achieved following clinical dosing. J Hepatol 2007; 46: 244-5.
60. Steven H, John AM, Michael TR. Discovery of MK-5172, a macrocyclic hepatitis C virus NS3/4a protease inhibitor. ACS Med Chem Lett 2012; 3: 332-6.
61. Cummings MD, et al. Induced-fit binding of the macrocyclic noncovalent inhibitorTMC435 to its HCV NS3/NS4A protease target. Angew Chem Int Ed Engl 2010; 49: 1652-55.
62. Prongay AJ, et al. Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization. J Med Chem 2007; 50: 2310-8.
63. Guo Z, Prongy A, Tong X, Fischmann T, Bogen S, Madison V. Computational study of the effects of mutations A156T, D168V, and D168Q on the binding of HCV protease inhibitors. J Chem Theory Comput 2006; 2: 1657-63.
64. Zeuzem S, Sarrarin C, Wagner F, Rouzier R, Cutler D, Zhang J. Combination therapy with HCV protease inhibitor SCH 503034, plus PEG-intron in hepatitis C genotype-1 PEG-intron nonresponders: phase 1b results. Hepatology 2005; 42 (Suppl. 1): 276A.
65. Seiwert SD, Andrews SW, Jiang Y, Blatt LM. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob Agents Chemother 2008; 52: 4432-41.
66. Lenz O, et al. In vitro resistance profile of the HCV NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 2010; 54: 1878-87.
67. Kuntzen T, et al. Naturally occurring dominant resistance mutations to hepatitisC virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 2008; 48: 1769-78.
68. Lemkel C T, Goudreau N. Combined X-ray, NMR, and kinetic analyses reveal uncommon binding characteristics of the hepatitis C virus NS3-NS4A protease inhibitor BI 201335. J Biol Chem 2011; 286: 11434-43.
69. Cummings MD, Lindberg J, Lin TI, Simmen K. Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease target. Angew Chem Int Ed 2010; 49: 1652-5.
70. Xue WW, Pan DB, Yang Y, Liu HX, Yao XJ. Molecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K, A156V and D168A to TMC435. Antiviral Res 2012; 93: 126-37.
71. Neumann GA, Mazarico E. Planetary science. Seeing the missing half. Science 2009; 323: 885-7.
72. Domingo E, Gomez J. Quasispecies and its impact on viral hepatitis. Virus Res 2007; 127: 131-50.
73. Franco S, Parera M, Aparicio E, Clotet B, Martinez MA. Genetic and catalytic efficiency structure of an HCV protease quasispecies. Hepatology 2007; 45: 899-910.
74. Richman DD. The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B. Hepatology 2000; 32: 866-7.
75. Monto A, Schooley RT, Lai JC, et al. Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop. Am J Gastroenterol 2010; 105: 989-1004.
76. Nelson DR. The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naive patients. Liver Int 2011; 31(suppl 1): 53-7.
77. Erhardt A, Deterding K, Benhamou Y, et al. Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment. Antivir Ther 2009; 14: 23-32.
78. Mccown MF, Rajyaguru S, Kular S, Cammack N, Najera I. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob Agents Chemother 2009; 53: 2129-32.
79. Mccown MF, Rajyaguru S, Le Pogam S, et al. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother 2008; 52: 1604-12.
80. Zeuzem S, Asselah T, Angus P, et al. Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients with Chronic HCV infection. Gastroenterology 2011; 141: 2047-55.
81. Zhou Y, Muh U, Hanzelka BL, et al. Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha. J Biol Chem 2007; 282: 22619-28.
82. Hao GF, Yang GF, Zhan CG. Structure-based methods for predicting target mutation-induced drug resistance and rational drug design to overcome the problem. Drug Discov Today 2012; 17: 1121-6.
83. Nalam MNL, Schiffer CA. New Approaches to HIV protease inhibitor drug design II: Testing the substrate envelope hypothesis to avoid drug resistance and discover robust inhibitors. Curr Opin HIV AIDS 2008; 3: 642-6.